Bedside Abdominal Ultrasound for Ruptured Abdominal Aortic Aneurysm: Diagnosis and Management

This patient is likely experiencing a ruptured abdominal aortic aneurysm (AAA), a life-threatening medical emergency. Bedside abdominal ultrasound (US) is the best initial diagnostic test for ruling out AAA as a cause of abdominal or back pain, as it provides an instant, objective measurement of aortic diameter. An AAA is a dilatation of the abdominal aorta greater than 3 cm in diameter, with a significant risk of rupture at diameters greater than 5 cm. Risk factors for AAA include smoking and co-existing vascular disease. Symptoms of a ruptured AAA include pain, cardiovascular failure, and distal ischemia. Once diagnosed, a CT angiogram is the gold-standard imaging for planning surgery to repair the aneurysm. Endoscopic retrograde cholangiopancreatography and liver function tests are not indicated in this case, while serum amylase or lipase should be measured in all patients presenting with acute abdominal or upper back pain to exclude acute pancreatitis as a differential diagnosis.

Treatment Options for Chlamydia Infections

Chlamydia trachomatis is a common sexually transmitted infection that can be effectively treated with antibiotics. The National Institute for Health and Care Excellence (NICE) provides guidance on the appropriate antimicrobial prescribing for chlamydia infections.

The first-line treatment for chlamydia is a 7-day course of doxycycline. This medication is highly effective against Chlamydia trachomatis and is well-tolerated by most patients. If doxycycline cannot be used, such as in cases of pregnancy or allergy, a 7-day course of azithromycin can be given as a second-line option.

It is important for patients to complete their full course of antibiotics and to avoid sexual intercourse until treatment is complete. If the treatment is completed, there is no need for a test of cure to be carried out.

Other antibiotics, such as oral penicillin and cefalexin, are not effective against chlamydia infections. A one-off dose of intramuscular ceftriaxone is the treatment of choice for gonorrhoea infections, but it is not indicated for the treatment of chlamydia.

Treatment Options for Sexually Transmitted Diseases

Sexually transmitted diseases (STDs) can present with a variety of symptoms and signs. The most common STD is Chlamydia trachomatis, which can be asymptomatic or present with dysuria, abdominal pain, and vaginal discharge. Endocervical and high vaginal swabs should be taken, and a urinalysis and pregnancy test should be completed. The first-line treatment for C. trachomatis is doxycycline.

Ceftriaxone is indicated for Neisseria gonorrhoeae infections, which can present similarly to chlamydia with discharge and dysuria. However, the most likely diagnosis for this patient is C. trachomatis, making doxycycline the correct answer.

Benzylpenicillin is used in patients with suspected syphilis infection secondary to the spirochaete Treponema pallidum. Syphilis has primary, secondary, and tertiary stages with primary syphilis presenting as a painless chancre with local, non-tender lymphadenopathy prior to secondary disease with fever and a rash. This is not seen here, making syphilis a less likely diagnosis.

Metronidazole is the recommended treatment for bacterial vaginosis and Trichomonas vaginalis. However, it is not used in the treatment of C. trachomatis.

Trimethoprim would be the recommended treatment if this patient was diagnosed with a urinary-tract infection (UTI). While the history of lower abdominal pain and dysuria are suggestive of a UTI, a foul-smelling vaginal discharge points towards an alternative diagnosis.

If a patient experiences severe symptoms of Campylobacter infection such as bloody diarrhea and more than eight stools per day, treatment with clarithromycin may be necessary. While Campylobacter infection is typically self-limiting, the British National Formulary (BNF) recommends antibiotics for severe cases or for immunocompromised patients. NICE also advises antibiotic treatment for severe symptoms or if symptoms persist for more than one week. Supportive treatment may be sufficient for mild symptoms in immunocompetent patients. Ciprofloxacin is an alternative to clarithromycin, but strains with decreased sensitivity to ciprofloxacin are frequently isolated. Metronidazole and oral vancomycin are not recommended for Campylobacter treatment, but are first-line options for Clostridium difficile.

Campylobacter: The Most Common Bacterial Cause of Intestinal Disease in the UK

Campylobacter is a Gram-negative bacillus that is responsible for causing infectious intestinal disease in the UK. The bacteria is primarily spread through the faecal-oral route and has an incubation period of 1-6 days. Symptoms of Campylobacter infection include a prodrome of headache and malaise, diarrhoea (often bloody), and abdominal pain that may mimic appendicitis.

In most cases, Campylobacter infection is self-limiting and does not require treatment. However, the British National Formulary (BNF) recommends treatment with antibiotics if the patient is immunocompromised or if symptoms are severe (high fever, bloody diarrhoea, or more than eight stools per day) and have lasted for more than one week. The first-line antibiotic for Campylobacter infection is clarithromycin, although ciprofloxacin is an alternative. It is important to note that strains with decreased sensitivity to ciprofloxacin are frequently isolated.

Complications of Campylobacter infection may include Guillain-Barre syndrome, reactive arthritis, septicaemia, endocarditis, and arthritis. It is important to seek medical attention if symptoms are severe or persist for an extended period of time.

The Importance of Lymph Node Biopsy in Diagnosing Hodgkin’s Lymphoma

When it comes to diagnosing Hodgkin’s lymphoma, a lymph node biopsy is the most reliable method. Fine-needle aspiration should not be used as the sole method for diagnosis. In addition to the biopsy, a thorough evaluation should include a medical history and examination, blood tests, liver function tests, serum protein tests, HIV testing, chest radiograph, CT scans, and bone marrow biopsy. Gallium scans can also be performed to document radioisotope uptake by the tumor. Lymphangiography may be necessary if the presentation of Hodgkin’s lymphoma is subdiaphragmatic. While a raised ESR can indicate Hodgkin’s lymphoma, it is not the most important step in obtaining a diagnosis. Similarly, repeating a CRP test or blood cultures would not be appropriate if the initial results were negative. In summary, a lymph node biopsy is crucial in diagnosing Hodgkin’s lymphoma and should be the first step in the evaluation process.

Primary amenorrhoea is caused by Turner’s syndrome instead of secondary amenorrhoea.

Understanding Amenorrhoea: Causes, Investigations, and Management

Amenorrhoea is a condition characterized by the absence of menstrual periods in women. It can be classified into two types: primary and secondary. Primary amenorrhoea occurs when menstruation fails to start by the age of 15 in girls with normal secondary sexual characteristics or by the age of 13 in girls with no secondary sexual characteristics. On the other hand, secondary amenorrhoea is the cessation of menstruation for 3-6 months in women with previously normal and regular menses or 6-12 months in women with previous oligomenorrhoea.

There are various causes of amenorrhoea, including gonadal dysgenesis, testicular feminization, congenital malformations of the genital tract, functional hypothalamic amenorrhoea, congenital adrenal hyperplasia, imperforate hymen, hypothalamic amenorrhoea, polycystic ovarian syndrome, hyperprolactinemia, premature ovarian failure, Sheehan’s syndrome, Asherman’s syndrome, and thyrotoxicosis. To determine the underlying cause of amenorrhoea, initial investigations such as full blood count, urea & electrolytes, coeliac screen, thyroid function tests, gonadotrophins, prolactin, and androgen levels are necessary.

The management of amenorrhoea depends on the underlying cause. For primary amenorrhoea, it is important to investigate and treat any underlying cause. Women with primary ovarian insufficiency due to gonadal dysgenesis may benefit from hormone replacement therapy to prevent osteoporosis. For secondary amenorrhoea, it is important to exclude pregnancy, lactation, and menopause in women 40 years of age or older and treat the underlying cause accordingly. It is important to note that hypothyroidism may also cause amenorrhoea.

Paracetamol overdose leads to a liver disease characterized by hepatocellular symptoms. This type of liver disease is different from cholestatic (obstructive) or mixed liver diseases, which have distinct laboratory test results. Hepatocellular disease is indicated by raised ALT levels, while cholestatic disease is indicated by raised ALP levels. Mixed liver disease has raised levels of both ALT and ALP. AST and ALT are both produced by hepatocytes, and in hepatocellular disease, these enzymes are released into the bloodstream, causing raised ALT levels. ALP, on the other hand, is produced by the cells lining the bile ducts, and its levels rise in obstructive liver disease.

Understanding Drug-Induced Liver Disease

Drug-induced liver disease is a condition that occurs when certain medications or drugs cause damage to the liver. This condition is generally divided into three categories: hepatocellular, cholestatic, or mixed. However, there is often overlap between these categories, as some drugs can cause a range of changes to the liver.

Hepatocellular drug-induced liver disease is characterized by damage to the liver cells. Some of the drugs that tend to cause this type of damage include paracetamol, sodium valproate, phenytoin, MAOIs, halothane, anti-tuberculosis medications, statins, alcohol, amiodarone, methyldopa, and nitrofurantoin.

Cholestatic drug-induced liver disease, on the other hand, is characterized by a reduction in bile flow from the liver. Some of the drugs that tend to cause this type of damage include the combined oral contraceptive pill, antibiotics such as flucloxacillin, co-amoxiclav, and erythromycin, anabolic steroids, testosterones, phenothiazines such as chlorpromazine and prochlorperazine, sulphonylureas, fibrates, and rare reported causes such as nifedipine. Methotrexate, methyldopa, and amiodarone can cause both hepatocellular and cholestatic damage.

It is important to note that drug-induced liver disease can be a serious condition and can lead to liver cirrhosis if left untreated. Therefore, it is important to be aware of the potential risks associated with certain medications and to seek medical attention if any symptoms of liver damage occur.

If a patient experiences a recurrent episode of C. difficile within 12 weeks of symptom resolution, it is recommended to treat them with oral fidaxomicin. However, the use of bezlotoxumab to prevent recurrences is not currently supported by NICE due to cost-effectiveness concerns. Faecal microbiota transplant may be considered for patients who have had two or more previous episodes, but not on the first recurrence. In cases of life-threatening Clostridium difficile infection, both oral vancomycin and IV metronidazole should be used for treatment.

Clostridioides difficile is a type of bacteria that is commonly found in hospitals. It is a Gram positive rod that produces an exotoxin which can cause damage to the intestines, leading to a condition called pseudomembranous colitis. This bacteria usually develops when the normal gut flora is suppressed by broad-spectrum antibiotics, with second and third generation cephalosporins being the leading cause of C. difficile. Other risk factors include proton pump inhibitors. Symptoms of C. difficile include diarrhea, abdominal pain, and a raised white blood cell count. The severity of the infection can be determined using the Public Health England severity scale, which ranges from mild to life-threatening.

To diagnose C. difficile, a stool sample is tested for the presence of C. difficile toxin (CDT). Treatment for a first episode of C. difficile infection typically involves oral vancomycin for 10 days, with fidaxomicin or a combination of oral vancomycin and IV metronidazole being used as second and third-line therapies. Recurrent infections occur in around 20% of patients, increasing to 50% after their second episode. In such cases, oral fidaxomicin is recommended within 12 weeks of symptom resolution, while oral vancomycin or fidaxomicin can be used after 12 weeks. For life-threatening C. difficile infections, oral vancomycin and IV metronidazole are used, and surgery may be considered with specialist advice. Other therapies, such as bezlotoxumab and fecal microbiota transplant, may also be considered for preventing recurrences in certain cases.

If a foetal heartbeat is detected on ultrasound in the case of an ectopic pregnancy, surgical management is necessary, and the appropriate procedure is a salpingectomy. This is the recommended course of action for a patient with no significant medical history and both fallopian tubes. Expectant management is not suitable in this scenario, as the foetal heartbeat is visible on ultrasound. Medical management with methotrexate is also not an option due to the foetal heartbeat, and mifepristone is not used for ectopic pregnancies.

Ectopic pregnancy is a serious condition that requires prompt investigation and management. Women who are stable are typically investigated and managed in an early pregnancy assessment unit, while those who are unstable should be referred to the emergency department. The investigation of choice for ectopic pregnancy is a transvaginal ultrasound, which will confirm the presence of a positive pregnancy test.

There are three ways to manage ectopic pregnancies: expectant management, medical management, and surgical management. The choice of management will depend on various criteria, such as the size of the ectopic pregnancy, whether it is ruptured or not, and the patient’s symptoms and hCG levels. Expectant management involves closely monitoring the patient over 48 hours, while medical management involves giving the patient methotrexate and requires follow-up. Surgical management can involve salpingectomy or salpingotomy, depending on the patient’s risk factors for infertility.

Salpingectomy is the first-line treatment for women with no other risk factors for infertility, while salpingotomy should be considered for women with contralateral tube damage. However, around 1 in 5 women who undergo a salpingotomy require further treatment, such as methotrexate and/or a salpingectomy. It is important to carefully consider the patient’s individual circumstances and make a decision that will provide the best possible outcome.

As the woman is experiencing symptoms, she requires treatment with a pregnancy-safe antibiotic. Trimethoprim is not recommended for use during the first trimester of pregnancy, making nitrofurantoin the appropriate choice. According to NICE CKS, amoxicillin should not be used due to its high resistance levels.

Urinary tract infections (UTIs) are common in adults and can affect different parts of the urinary tract. The management of UTIs depends on various factors such as the patient’s age, gender, and pregnancy status. For non-pregnant women, local antibiotic guidelines should be followed if available. Trimethoprim or nitrofurantoin for three days are recommended by NICE Clinical Knowledge Summaries. However, if the patient is aged over 65 years or has visible or non-visible haematuria, a urine culture should be sent. Pregnant women with UTIs should be treated with nitrofurantoin, amoxicillin, or cefalexin for seven days. Trimethoprim should be avoided during pregnancy as it is teratogenic in the first trimester. Asymptomatic bacteriuria in pregnant women should also be treated to prevent progression to acute pyelonephritis. Men with UTIs should be offered a seven-day course of trimethoprim or nitrofurantoin unless prostatitis is suspected. A urine culture should be sent before antibiotics are started. Catheterised patients should not be treated for asymptomatic bacteria, but if symptomatic, a seven-day course of antibiotics should be given. Acute pyelonephritis requires hospital admission and treatment with a broad-spectrum cephalosporin or quinolone for 10-14 days. Referral to urology is not routinely required for men who have had one uncomplicated lower UTI.

A woman with a moderate or high risk of pre-eclampsia, such as this patient who has a family history of pre-eclampsia and type 1 diabetes mellitus, should take aspirin 75-150mg daily from 12 weeks gestation until delivery to reduce the risk of developing pre-eclampsia.

Pre-eclampsia is a condition that occurs during pregnancy and is characterized by high blood pressure, proteinuria, and edema. It can lead to complications such as eclampsia, neurological issues, fetal growth problems, liver involvement, and cardiac failure. Severe pre-eclampsia is marked by hypertension, proteinuria, headache, visual disturbances, and other symptoms. Risk factors for pre-eclampsia include hypertension in a previous pregnancy, chronic kidney disease, autoimmune disease, diabetes, chronic hypertension, first pregnancy, and age over 40. Aspirin may be recommended for women with high or moderate risk factors. Treatment involves emergency assessment, admission for observation, and medication such as labetalol, nifedipine, or hydralazine. Delivery of the baby is the most important step in management, with timing depending on the individual case.

Possible Causes of Hypertension: Differential Diagnosis

Hypertension in a young patient may indicate a secondary cause, such as renovascular disease. In this case, a small kidney on ultrasound and elevated creatinine levels suggest renal artery stenosis as a possible cause. Other potential diagnoses, such as Cushing’s syndrome, acromegaly, and phaeochromocytoma, are less likely based on the absence of corresponding symptoms and signs. Polycystic kidney disease, which can also cause hypertension, would typically present with bilateral renal enlargement rather than atrophy. A thorough differential diagnosis is important to identify the underlying cause of hypertension and guide appropriate management.

Levonorgestrel (Levonelle) can be followed immediately by hormonal contraception for emergency contraception.

Patients can resume their regular pill regimen right after taking levonorgestrel for emergency contraception. Levonorgestrel is an approved method of emergency contraception that can be used within 72 hours of unprotected sexual intercourse. It is the preferred oral emergency contraceptive for patients with asthma, as ulipristal is not recommended for those with severe asthma. Unlike ulipristal, which requires a waiting period of 5 days, patients can start hormonal contraception immediately after taking levonorgestrel. However, patients should use condoms for 7 days after restarting their combined oral contraceptive pill (COCP). It is important to note that the other options provided are incorrect. The progesterone-only pill requires condom use for 48 hours, unless initiated within the first 5 days of the menstrual cycle. Ulipristal acetate requires a waiting period of 5 days before restarting hormonal contraception. The COCP requires condom use for 7 days after restarting.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.

Travel-Related Illnesses: Symptoms, Diagnosis, and Treatment

Malaria, Yellow Fever, Enteric Fever, Hepatitis A, and Schistosomiasis are some of the common travel-related illnesses that can affect people visiting certain parts of the world.

Malaria is a potentially life-threatening illness caused by a parasite transmitted by mosquitoes. Symptoms include headache, cough, fatigue, fever with rigors, nausea, vomiting, and diarrhea. Diagnosis is made through thick and thin blood films, and treatment should be guided by an infectious disease specialist.

Yellow fever is an insect-borne tropical disease with symptoms that may include a flu-like illness, jaundice, and abnormal bleeding. It has a short incubation period of 3-6 days and is transmitted by mosquitoes. Vaccination is recommended for travelers to high-risk areas.

Enteric fever is caused by salmonella typhoid or paratyphoid and is transmitted orally via contaminated food or drink. Symptoms include severe flu-like symptoms, especially diarrhea and fever. Diagnosis is made through blood cultures, and treatment is with antibiotics.

Hepatitis A is a viral infection transmitted via contaminated food or water. Symptoms include a flu-like illness, jaundice, and tender hepatomegaly. Diagnosis is made through blood tests, and treatment is supportive.

Schistosomiasis is a parasitic infection spread by flatworms that live in freshwater. Symptoms can include fever, rash, abdominal pain, and diarrhea. Chronic infection may present as rectal bleeding, hematuria, anemia, or cystitis. Diagnosis is made through blood and stool tests, and treatment is with antiparasitic medication.

In conclusion, travelers to certain parts of the world should be aware of the risk of these illnesses and take appropriate precautions, including vaccination, prophylaxis, and avoiding contaminated food and water. If symptoms develop, prompt medical attention should be sought.

Understanding the Signs and Symptoms of Frontotemporal Dementia and Lewy Body Dementia

Frontotemporal dementia (FTD) and Lewy body dementia (LBD) are two types of dementia that can cause a range of symptoms. Understanding the signs and symptoms of these conditions can help with early diagnosis and treatment.

Fluctuating confusion and hallucination are common signs of LBD, which is caused by protein deposits in nerve cells in the brain. People with LBD may also experience Parkinson’s disease symptoms such as rigid muscles and tremors. On the other hand, FTD is characterized by an insidious onset and a gradual progression. Personality changes, social-conduct problems, and a decline in judgment and empathy are common features of FTD.

While memory loss is a more prominent symptom in early Alzheimer’s, it can also occur in advanced stages of FTD and LBD. However, relatively preserved memory is more characteristic of FTD in its early stages. Additionally, FTD tends to have an onset before age 65, with some cases diagnosed in individuals as young as 17 years old.

Overall, recognizing the signs and symptoms of FTD and LBD can help with early diagnosis and management of these conditions.

To decrease the risk of relapse, it is recommended to continue antidepressant treatment for at least 6 months after remission of symptoms. Therefore, the correct response is to continue fluoxetine for at least 6 months at the same dose. It should be noted that in elderly patients, treatment should be continued for 12 months, and in those with a history of recurrent depression, treatment should be continued for 2 years. Stopping fluoxetine or tapering the dose over 2 weeks is not appropriate, as treatment should be continued for at least 6 months before considering stopping or tapering. When fluoxetine is stopped, it is recommended to taper the dose over 6-12 weeks to minimize the risk of withdrawal symptoms.

Selective serotonin reuptake inhibitors (SSRIs) are commonly used as the first-line treatment for depression. Citalopram and fluoxetine are the preferred SSRIs, while sertraline is recommended for patients who have had a myocardial infarction. However, caution should be exercised when prescribing SSRIs to children and adolescents. Gastrointestinal symptoms are the most common side-effect, and patients taking SSRIs are at an increased risk of gastrointestinal bleeding. Patients should also be aware of the possibility of increased anxiety and agitation after starting a SSRI. Fluoxetine and paroxetine have a higher propensity for drug interactions.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning regarding the use of citalopram due to its association with dose-dependent QT interval prolongation. As a result, citalopram and escitalopram should not be used in patients with congenital long QT syndrome, known pre-existing QT interval prolongation, or in combination with other medicines that prolong the QT interval. The maximum daily dose of citalopram is now 40 mg for adults, 20 mg for patients older than 65 years, and 20 mg for those with hepatic impairment.

When initiating antidepressant therapy, patients should be reviewed by a doctor after 2 weeks. Patients under the age of 25 years or at an increased risk of suicide should be reviewed after 1 week. If a patient responds well to antidepressant therapy, they should continue treatment for at least 6 months after remission to reduce the risk of relapse. When stopping a SSRI, the dose should be gradually reduced over a 4 week period, except for fluoxetine. Paroxetine has a higher incidence of discontinuation symptoms, including mood changes, restlessness, difficulty sleeping, unsteadiness, sweating, gastrointestinal symptoms, and paraesthesia.

When considering the use of SSRIs during pregnancy, the benefits and risks should be weighed. Use during the first trimester may increase the risk of congenital heart defects, while use during the third trimester can result in persistent pulmonary hypertension of the newborn. Paroxetine has an increased risk of congenital malformations, particularly in the first trimester.

Common Elbow Pain Symptoms and Their Features

Elbow pain can be caused by various conditions, each with its own set of symptoms. Here are some common elbow pain symptoms and their features:

1. Lateral Epicondylitis (Tennis Elbow)
– Pain and tenderness localized to the lateral epicondyle
– Pain worsens on resisted wrist extension with the elbow extended or supination of the forearm with the elbow extended
– Episodes typically last between six months and two years; patients tend to have acute pain for 6-12 weeks
– Pain aggravated by wrist flexion and pronation

2. Medial Epicondylitis (Golfer’s Elbow)
– Pain and tenderness localized to the medial epicondyle
– Pain aggravated by wrist flexion and pronation
– Symptoms may be accompanied by numbness/tingling in the fourth and fifth fingers due to ulnar-nerve involvement

3. Cubital Tunnel Syndrome
– Initially intermittent tingling in the fourth and fifth fingers
– Pain worsens when the elbow is resting on a firm surface or flexed for extended periods
– Later numbness in the fourth and fifth fingers with associated weakness

4. Carpal Tunnel Syndrome
– Pain worsens when the wrists are in complete flexion for at least 30 seconds
– The Phalen test is done to investigate its presence

5. Olecranon Bursitis
– Swelling over the posterior aspect of the elbow with associated pain, warmth, and erythema
– Typically affects middle-aged male patients

Understanding Common Symptoms of Elbow Pain

Pancreatic cancer is best diagnosed through high-resolution CT scanning. Although chronic pancreatitis increases the risk, neither alcohol nor gallstone disease are significant independent risk factors. Radiotherapy is not effective for surgical resection. Unfortunately, most patients are diagnosed with unresectable lesions.

Understanding Pancreatic Cancer: Risk Factors, Symptoms, and Management

Pancreatic cancer is a type of cancer that is often diagnosed late due to its non-specific symptoms. Adenocarcinomas, which occur at the head of the pancreas, make up over 80% of pancreatic tumors. Risk factors for pancreatic cancer include increasing age, smoking, diabetes, chronic pancreatitis, hereditary non-polyposis colorectal carcinoma, and genetic mutations such as BRCA2 and KRAS.

Symptoms of pancreatic cancer can include painless jaundice, pale stools, dark urine, pruritus, anorexia, weight loss, epigastric pain, loss of exocrine and endocrine function, and atypical back pain. Migratory thrombophlebitis, also known as Trousseau sign, is more common in pancreatic cancer than in other cancers.

Diagnosis of pancreatic cancer can be made through ultrasound or high-resolution CT scanning, which may show the double duct sign – simultaneous dilatation of the common bile and pancreatic ducts. However, less than 20% of patients are suitable for surgery at diagnosis. A Whipple’s resection, or pancreaticoduodenectomy, may be performed for resectable lesions in the head of the pancreas. Adjuvant chemotherapy is usually given following surgery, and ERCP with stenting may be used for palliation.

In summary, pancreatic cancer is a serious disease with non-specific symptoms that can be difficult to diagnose. Understanding the risk factors and symptoms can help with early detection and management.

Management of Suspected Giant-Cell Arteritis

Giant-cell arteritis (GCA) is a medical emergency that requires prompt diagnosis and treatment to prevent irreversible loss of vision. The following are the appropriate steps in managing a patient with suspected GCA:

Prompt Management of Suspected Giant-Cell Arteritis

1. Start oral steroids immediately: Delaying treatment can lead to vision loss. Steroids should be initiated even before the diagnosis is confirmed by temporal artery biopsy.

2. Admit and start on methotrexate if necessary: Patients on steroids are at high risk of side effects. Methotrexate or tocilizumab can be used in those who have steroid toxicity, along with tapering doses of steroids.

3. Arrange an urgent temporal artery biopsy: This is the gold-standard investigation for GCA. However, treatment should not be delayed till after the biopsy.

4. Do not refer to a rheumatologist on an outpatient basis: A rheumatologist will eventually be involved in the management of GCA, but immediate treatment is necessary.

5. Do not arrange an MRI scan of the brain: This is not indicated in the usual evaluation of GCA. It is used in specific cases of extracranial GCA or when there is strong clinical suspicion but a negative temporal artery biopsy.

The use of diclofenac is now prohibited for individuals with any type of cardiovascular ailment.

MHRA Guidance on Diclofenac and Cardiovascular Safety

The MHRA has updated its guidance on diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), after a Europe-wide review of cardiovascular safety. While it has been known for some time that NSAIDs may increase the risk of cardiovascular events, the evidence base has become clearer. Diclofenac is associated with a significantly higher risk of cardiovascular events compared to other NSAIDs. Therefore, it is contraindicated in patients with ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, and congestive heart failure (New York Heart Association classification II-IV). Patients should switch from diclofenac to other NSAIDs such as naproxen or ibuprofen, except for topical diclofenac. Studies have shown that naproxen and low-dose ibuprofen have the best cardiovascular risk profiles of the NSAIDs.

The MHRA’s updated guidance on diclofenac and cardiovascular safety highlights the increased risk of cardiovascular events associated with this NSAID compared to other NSAIDs. Patients with certain conditions are advised to avoid diclofenac and switch to other NSAIDs. This guidance is important for healthcare professionals to consider when prescribing NSAIDs to patients with cardiovascular risk factors.

Bell’s palsy affects the lower motor neurons and results in weakness of the entire side of the face. A left cranial nerve VII lower motor neuron lesion would cause left-sided facial weakness without forehead sparing. However, lateral medullary syndrome, caused by ischemia to the lateral medulla oblongata, would present with vertigo, dizziness, nystagmus, ataxia, nausea and vomiting, and dysphagia. A left cranial nerve VII upper motor neuron lesion would result in right-sided facial weakness with forehead sparing, while a right cranial nerve VII lower motor neuron lesion would cause right-sided facial weakness without forehead sparing.

Understanding Bell’s Palsy

Bell’s palsy is a sudden, one-sided facial nerve paralysis of unknown cause. It is more common in individuals aged 20-40 years and pregnant women. The condition is characterized by lower motor neuron facial nerve palsy, which affects the forehead. Unlike upper motor neuron lesions, the upper face is spared. Patients may also experience post-auricular pain, altered taste, dry eyes, and hyperacusis.

The management of Bell’s palsy has been a subject of debate. However, it is now widely accepted that all patients should receive oral prednisolone within 72 hours of onset. The addition of antiviral medications is still a matter of discussion, but it may be beneficial for severe facial palsy. Eye care is also crucial to prevent exposure keratopathy, and patients should be prescribed artificial tears and eye lubricants. If they are unable to close their eyes at bedtime, they should tape them closed using microporous tape.

If the paralysis shows no sign of improvement after three weeks, an urgent referral to ENT is necessary. Patients with long-standing weakness may require a referral to plastic surgery. The prognosis for Bell’s palsy is generally good, with most patients making a full recovery within 3-4 months. However, untreated patients may experience permanent moderate to severe weakness in around 15% of cases.

Scleroderma (systemic sclerosis) frequently leads to malabsorption syndrome, which is characterized by reduced absorption of certain vitamins (B12, folate), nutrients (iron), and protein (low albumin) as indicated by blood tests.

Understanding Malabsorption: Causes and Symptoms

Malabsorption is a condition that is characterized by diarrhea, steatorrhea, and weight loss. It occurs when the body is unable to absorb nutrients from the food that is consumed. The causes of malabsorption can be broadly divided into three categories: intestinal, pancreatic, and biliary. Intestinal causes include conditions such as coeliac disease, Crohn’s disease, tropical sprue, Whipple’s disease, Giardiasis, and brush border enzyme deficiencies. Pancreatic causes include chronic pancreatitis, cystic fibrosis, and pancreatic cancer. Biliary causes include biliary obstruction and primary biliary cirrhosis. Other causes of malabsorption include bacterial overgrowth, short bowel syndrome, and lymphoma.

Understanding the Mechanisms of Sumatriptan: A Migraine and Cluster Headache Treatment

Sumatriptan is a medication commonly used to treat migraine and cluster headaches. It works by activating specific serotonin receptors (5-HT1D and 5-HT1B) found on cranial and basilar arteries, causing vasoconstriction of these blood vessels. This medication can be administered orally, by subcutaneous injection, or intranasally.

It is important to note that sumatriptan has no effect on adrenergic receptors or acetylcholinesterase receptors. It is also not a cyclooxygenase (COX) inhibitor or an opioid receptor agonist or antagonist.

In addition to its effects on blood vessels, sumatriptan has been shown to decrease the activity of the trigeminal nerve, which is responsible for its effectiveness in treating cluster headaches.

Overall, understanding the mechanisms of sumatriptan can help healthcare professionals and patients better understand how this medication works to alleviate the symptoms of migraine and cluster headaches.

These test results indicate that the patient has been previously immunized against hepatitis B. The vaccine used for immunization only contains the surface antigen, so the absence of antibodies to the core antigen is expected.

If the patient had an acute infection, they would test positive for the hepatitis B antigen and likely have positive IgG and IgM antibodies for the core antigen, but not for the surface antigen.

In the case of a chronic infection, the patient would test positive for the antigen and likely have a positive IgG antibody to the core protein, but a negative IgM antibody and no antibody response to the surface protein.

A negative result for all four tests would indicate no previous infection or immunization.

If the patient had a previous, resolved infection, they would test positive for both anti-HBs and anti-HBc, but the absence of HBsAg would indicate that they are not currently infected.

Interpreting hepatitis B serology is an important skill that is still tested in medical exams. It is crucial to keep in mind a few key points. The surface antigen (HBsAg) is the first marker to appear and triggers the production of anti-HBs. If HBsAg is present for more than six months, it indicates chronic disease, while its presence for one to six months implies acute disease. Anti-HBs indicates immunity, either through exposure or immunization, and is negative in chronic disease. Anti-HBc indicates previous or current infection, with IgM anti-HBc appearing during acute or recent hepatitis B infection and persisting IgG anti-HBc. HbeAg is a marker of infectivity and HBV replication.

To illustrate, if someone has been previously immunized, their anti-HBs will be positive, while all other markers will be negative. If they had hepatitis B more than six months ago but are not a carrier, their anti-HBc will be positive, and HBsAg will be negative. However, if they are now a carrier, both anti-HBc and HBsAg will be positive. If HBsAg is present, it indicates an ongoing infection, either acute or chronic if present for more than six months. On the other hand, anti-HBc indicates that the person has caught the virus, and it will be negative if they have been immunized.

Distinguishing between episcleritis and scleritis can be achieved using eye drops. By administering the drops, it is possible to observe whether the redness in the eye blanches or not. If it does, then the condition is episcleritis, but if it doesn’t, then it is scleritis. This skill is particularly valuable for those working in an Emergency Medicine rotation. None of the other options are useful for distinguishing between these two conditions.

Understanding Episcleritis

Episcleritis is a condition that involves the sudden onset of inflammation in the episclera of one or both eyes. While the majority of cases are idiopathic, there are some associated conditions such as inflammatory bowel disease and rheumatoid arthritis. Symptoms of episcleritis include a red eye, mild pain or irritation, watering, and mild photophobia. However, unlike scleritis, episcleritis is typically not painful.

One way to differentiate between the two conditions is by applying gentle pressure on the sclera. If the injected vessels are mobile, it is likely episcleritis. In contrast, scleritis involves deeper vessels that do not move. Phenylephrine drops may also be used to distinguish between the two conditions. If the eye redness improves after phenylephrine, a diagnosis of episcleritis can be made.

Approximately 50% of cases of episcleritis are bilateral. Treatment for episcleritis is typically conservative, with artificial tears sometimes being used. Understanding the symptoms and differences between episcleritis and scleritis can help individuals seek appropriate treatment and management for their eye condition.

Gestational diabetes is a common medical disorder affecting around 4% of pregnancies. Risk factors include a high BMI, previous gestational diabetes, and family history of diabetes. Screening is done through an oral glucose tolerance test, and diagnostic thresholds have recently been updated. Management includes self-monitoring of blood glucose, diet and exercise advice, and medication if necessary. For pre-existing diabetes, weight loss and insulin are recommended, and tight glycemic control is important. Targets for self-monitoring include fasting glucose of 5.3 mmol/l and 1-2 hour post-meal glucose levels.

The patient in question is likely suffering from glandular fever, a viral illness caused by the Ebstein-Barr virus. Symptoms include a sore throat, fever, and general malaise, as well as palpable cervical lymphadenopathy and an erythematous throat. The illness is more common in teenagers and is often spread through respiratory droplets, earning it the nickname kissing disease. The patient was prescribed amoxicillin by their GP, which can cause a non-specific maculopapular rash in patients with glandular fever. The diagnosis is typically confirmed through a Monospot blood test, which detects the presence of heterophil antibodies produced in response to the virus.

An anti-streptolysin O titre test can detect streptococcal infections, but it does not explain the patient’s rash following antibiotic use. A full blood count can be helpful in diagnosing glandular fever, as it often shows a lymphocytosis, but the Monospot test is more definitive. A nasopharyngeal aspirate for viral PCR can diagnose viral infections like measles, but this is less likely in a teenager in the UK due to vaccination. A sputum culture is not useful in diagnosing glandular fever, as the patient does not have a cough or sputum production.

Understanding Infectious Mononucleosis

Infectious mononucleosis, also known as glandular fever, is a viral infection caused by the Epstein-Barr virus (EBV) in 90% of cases. It is most commonly seen in adolescents and young adults. The classic triad of symptoms includes sore throat, pyrexia, and lymphadenopathy, which are present in around 98% of patients. Other symptoms include malaise, anorexia, headache, palatal petechiae, splenomegaly, hepatitis, lymphocytosis, haemolytic anaemia, and a maculopapular rash. The symptoms typically resolve after 2-4 weeks.

The diagnosis of infectious mononucleosis is confirmed through a heterophil antibody test (Monospot test) in the second week of the illness. Management is supportive and includes rest, drinking plenty of fluids, avoiding alcohol, and taking simple analgesia for any aches or pains. It is recommended to avoid playing contact sports for 4 weeks after having glandular fever to reduce the risk of splenic rupture.

Interestingly, there is a correlation between EBV and socioeconomic groups. Lower socioeconomic groups have high rates of EBV seropositivity, having frequently acquired EBV in early childhood when the primary infection is often subclinical. However, higher socioeconomic groups show a higher incidence of infectious mononucleosis, as acquiring EBV in adolescence or early adulthood results in symptomatic disease.

The Royal College of Physicians (RCP) and NICE have published guidelines on the diagnosis and management of patients following a stroke. The management of acute stroke includes maintaining normal levels of blood glucose, hydration, oxygen saturation, and temperature. Blood pressure should not be lowered in the acute phase unless there are complications. Aspirin should be given as soon as possible if a haemorrhagic stroke has been excluded. Anticoagulants should not be started until brain imaging has excluded haemorrhage. Thrombolysis with alteplase should only be given if administered within 4.5 hours of onset of stroke symptoms and haemorrhage has been definitively excluded. Mechanical thrombectomy is a new treatment option for patients with an acute ischaemic stroke. NICE recommends thrombectomy for people who have acute ischaemic stroke and confirmed occlusion of the proximal anterior circulation demonstrated by computed tomographic angiography or magnetic resonance angiography. Secondary prevention includes the use of clopidogrel and dipyridamole. Carotid artery endarterectomy should only be considered if carotid stenosis is greater than 70% according to ECST criteria or greater than 50% according to NASCET criteria.

Lower gastrointestinal tract investigation should be conducted on any patient in this age group who has an unexplained microcytic anaemia to rule out the possibility of colorectal cancer.

Referral Guidelines for Colorectal Cancer

Colorectal cancer is a serious condition that requires prompt diagnosis and treatment. In 2015, the National Institute for Health and Care Excellence (NICE) updated their referral guidelines for patients suspected of having colorectal cancer. According to these guidelines, patients who are 40 years or older with unexplained weight loss and abdominal pain, 50 years or older with unexplained rectal bleeding, or 60 years or older with iron deficiency anemia or change in bowel habit should be referred urgently to colorectal services for investigation. Additionally, patients who test positive for occult blood in their feces should also be referred urgently.

An urgent referral should also be considered for patients who have a rectal or abdominal mass, unexplained anal mass or anal ulceration, or are under 50 years old with rectal bleeding and any of the following unexplained symptoms/findings: abdominal pain, change in bowel habit, weight loss, or iron deficiency anemia.

The NHS offers a national screening program for colorectal cancer, which involves sending eligible patients aged 60 to 74 years in England and 50 to 74 years in Scotland FIT tests through the post. FIT is a type of fecal occult blood test that uses antibodies to detect and quantify the amount of human blood in a single stool sample. Patients with abnormal results are offered a colonoscopy.

The FIT test is also recommended for patients with new symptoms who do not meet the 2-week criteria listed above. For example, patients who are 50 years or older with unexplained abdominal pain or weight loss, under 60 years old with changes in their bowel habit or iron deficiency anemia, or 60 years or older who have anemia even in the absence of iron deficiency. Early detection and treatment of colorectal cancer can significantly improve patient outcomes, making it important to follow these referral guidelines.

Transient Global Amnesia: A Temporary Disorder of Memory

Transient global amnesia (TGA) is a temporary and isolated disorder of memory that typically affects patients aged over 50. It is characterized by a sudden onset of anterograde amnesia, which can last for several hours. The patient retains remote memories and immediate recall, but has no memory of the event after recovery. TGA can be triggered by various factors, such as sexual intercourse, heavy exercise, and exposure to hot or cold water.

To diagnose TGA, all of the following criteria must be met: the attack was witnessed and reported, there was obvious anterograde amnesia during the attack, there was no clouding of consciousness, there were no focal neurological signs or deficits during or after the attack, there were no features of epilepsy, the attack resolved within 24 hours, and the patient did not have any recent head injury or active epilepsy.

Although there is a correlation between TGA and migraine, it is not associated with cerebrovascular disease. The condition usually resolves spontaneously, and there is a small risk of recurrence.

Other conditions that can cause memory loss or confusion include subarachnoid hemorrhage, right caudate hemorrhage, cerebral venous thrombosis, and right hemisphere TIA. However, these conditions have different clinical presentations and require different diagnostic criteria.

In conclusion, TGA is a benign condition that can cause temporary memory loss and confusion. It is important to recognize the characteristic features of TGA and differentiate it from other conditions that can cause similar symptoms.